With the 2025 WTA season barely a month in, American tennis star Peyton Stearns already has two unwelcome records to her name. The 23-year old has been part of some of the longest matches on tour this ...

It would have been nice to have a Pro Bowl on Nix's resume already. However, according to Peyton Manning, there are other benefits to the Pro Bowl games that Nix unfortunately opted to forgo.

While Mayfield is at the games, AFC Pro Bowl head coach and Hall of Fame quarterback Peyton Manning was asked about the Buccaneers franchise signal-caller. Jan 30, 2025; Orlando, FL, USA ...

However, in the last two years, it’s been the NFC, led by head coach Eli Manning, that has dominated the competition, beating the AFC, coached by Eli’s older brother, Peyton Manning.

The 19-year-old phenom, who is set to finally take over as a starter in the 2025 season, said he has been bullied by his famous uncles, Peyton and Eli, and they have even given him wedgies.

Acrivon Therapeutics, Inc. (ACRV – Research Report) received a Buy rating and price target from Cantor Fitzgerald analyst Li Watsek today. The company’s shares closed yesterday at $5.79.

Maye, who earned his first Pro Bowl nod this week as an alternate, drew praise from Peyton Manning for his leadership qualities. Manning is this year’s AFC coach. “You see, Drake, he’s very ...

Pro Football Hall of Fame quarterback Peyton Manning and entertainers Tim McGraw and Faith Hill. The group led by Bill Haslam, a former Tennessee governor, submitted its bid to the WNBA on ...

Milo Manheim is joined by his famous mom Camryn Manheim at the School Spirits season two premiere held at The Hollywood Roosevelt on Tuesday (January 28) in Los Angeles. The 23-year-old actor hit ...

Watsek anticipates that the biopharmaceutical company will earn ($1.67) per share for the year. The consensus estimate for Fate Therapeutics’ current full-year earnings is ($1.63) per share.

Watsek expects that the company will post earnings per share of ($5.29) for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Arcus Biosciences ...